What's next for cancer vaccines

Cancer vaccines have been shown clinically to drive tumor-reactive cell activation, proliferation, and effector function. Unfortunately, tumor eradication by treatment with cancer vaccines has been unsuccessful in many patients. Critical steps are under way to improve vaccine efficacy and combine th...

Full description

Saved in:
Bibliographic Details
Published in:Science translational medicine 2022-11, Vol.14 (670), p.eabo4632-eabo4632
Main Authors: Adamik, Juraj, Butterfield, Lisa H
Format: Article
Language:English
Subjects:
Cancer
Cancer vaccines
Cancer Vaccines - therapeutic use
Cell activation
Humans
Immunotherapy
Neoplasms - therapy
Tumors
Vaccine efficacy
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c381t-6b561d8d2d83c199f4f6137e683ad7d86750b2013daf617a0a6f60c9d2f01a2a3
cites cdi_FETCH-LOGICAL-c381t-6b561d8d2d83c199f4f6137e683ad7d86750b2013daf617a0a6f60c9d2f01a2a3
container_end_page eabo4632
container_issue 670
container_start_page eabo4632
container_title Science translational medicine
container_volume 14
creator Adamik, Juraj
Butterfield, Lisa H
description Cancer vaccines have been shown clinically to drive tumor-reactive cell activation, proliferation, and effector function. Unfortunately, tumor eradication by treatment with cancer vaccines has been unsuccessful in many patients. Critical steps are under way to improve vaccine efficacy and combine them with immunotherapy and standard-of-care treatments.
doi_str_mv 10.1126/scitranslmed.abo4632
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2735166971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2735558152</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-6b561d8d2d83c199f4f6137e683ad7d86750b2013daf617a0a6f60c9d2f01a2a3</originalsourceid><addsrcrecordid>eNpdkFtLw0AQhRdRbK3-A9GAD_qSupfsJPsoxRsUfFF8XCZ7wZQ0qbuJ6L83ta2ITzPMfOfMcAg5ZXTKGIfraKouYBPrpbNTLNsMBN8jY6YySIFnfP-3F9mIHMW4oBQKIeGQjAQISZXiY3L--obdZUwa99klvg2Jwca4kHygMVXj4jE58FhHd7KtE_Jyd_s8e0jnT_ePs5t5akTBuhRKCcwWlttCGKaUzzwwkbvhINrcFpBLWnLKhMVhkSNF8ECNstxThhzFhFxtfFehfe9d7PSyisbVNTau7aPmuZAMQOVsQC_-oYu2D83w3Q8lZcEkH6hsQ5nQxhic16tQLTF8aUb1OkD9N0C9DXCQnW3N-3I934l2iYlv_9xt8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2735558152</pqid></control><display><type>article</type><title>What's next for cancer vaccines</title><source>Alma/SFX Local Collection</source><creator>Adamik, Juraj ; Butterfield, Lisa H</creator><creatorcontrib>Adamik, Juraj ; Butterfield, Lisa H</creatorcontrib><description>Cancer vaccines have been shown clinically to drive tumor-reactive cell activation, proliferation, and effector function. Unfortunately, tumor eradication by treatment with cancer vaccines has been unsuccessful in many patients. Critical steps are under way to improve vaccine efficacy and combine them with immunotherapy and standard-of-care treatments.</description><identifier>ISSN: 1946-6234</identifier><identifier>EISSN: 1946-6242</identifier><identifier>EISSN: 1946-3242</identifier><identifier>DOI: 10.1126/scitranslmed.abo4632</identifier><identifier>PMID: 36350992</identifier><language>eng</language><publisher>United States: The American Association for the Advancement of Science</publisher><subject>Cancer ; Cancer vaccines ; Cancer Vaccines - therapeutic use ; Cell activation ; Humans ; Immunotherapy ; Neoplasms - therapy ; Tumors ; Vaccine efficacy ; Vaccines</subject><ispartof>Science translational medicine, 2022-11, Vol.14 (670), p.eabo4632-eabo4632</ispartof><rights>Copyright The American Association for the Advancement of Science Nov 9, 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-6b561d8d2d83c199f4f6137e683ad7d86750b2013daf617a0a6f60c9d2f01a2a3</citedby><cites>FETCH-LOGICAL-c381t-6b561d8d2d83c199f4f6137e683ad7d86750b2013daf617a0a6f60c9d2f01a2a3</cites><orcidid>0000-0002-3439-9844</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36350992$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adamik, Juraj</creatorcontrib><creatorcontrib>Butterfield, Lisa H</creatorcontrib><title>What's next for cancer vaccines</title><title>Science translational medicine</title><addtitle>Sci Transl Med</addtitle><description>Cancer vaccines have been shown clinically to drive tumor-reactive cell activation, proliferation, and effector function. Unfortunately, tumor eradication by treatment with cancer vaccines has been unsuccessful in many patients. Critical steps are under way to improve vaccine efficacy and combine them with immunotherapy and standard-of-care treatments.</description><subject>Cancer</subject><subject>Cancer vaccines</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Cell activation</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Neoplasms - therapy</subject><subject>Tumors</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><issn>1946-6234</issn><issn>1946-6242</issn><issn>1946-3242</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpdkFtLw0AQhRdRbK3-A9GAD_qSupfsJPsoxRsUfFF8XCZ7wZQ0qbuJ6L83ta2ITzPMfOfMcAg5ZXTKGIfraKouYBPrpbNTLNsMBN8jY6YySIFnfP-3F9mIHMW4oBQKIeGQjAQISZXiY3L--obdZUwa99klvg2Jwca4kHygMVXj4jE58FhHd7KtE_Jyd_s8e0jnT_ePs5t5akTBuhRKCcwWlttCGKaUzzwwkbvhINrcFpBLWnLKhMVhkSNF8ECNstxThhzFhFxtfFehfe9d7PSyisbVNTau7aPmuZAMQOVsQC_-oYu2D83w3Q8lZcEkH6hsQ5nQxhic16tQLTF8aUb1OkD9N0C9DXCQnW3N-3I934l2iYlv_9xt8Q</recordid><startdate>20221109</startdate><enddate>20221109</enddate><creator>Adamik, Juraj</creator><creator>Butterfield, Lisa H</creator><general>The American Association for the Advancement of Science</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3439-9844</orcidid></search><sort><creationdate>20221109</creationdate><title>What's next for cancer vaccines</title><author>Adamik, Juraj ; Butterfield, Lisa H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-6b561d8d2d83c199f4f6137e683ad7d86750b2013daf617a0a6f60c9d2f01a2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer</topic><topic>Cancer vaccines</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Cell activation</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Neoplasms - therapy</topic><topic>Tumors</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adamik, Juraj</creatorcontrib><creatorcontrib>Butterfield, Lisa H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Science translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adamik, Juraj</au><au>Butterfield, Lisa H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What's next for cancer vaccines</atitle><jtitle>Science translational medicine</jtitle><addtitle>Sci Transl Med</addtitle><date>2022-11-09</date><risdate>2022</risdate><volume>14</volume><issue>670</issue><spage>eabo4632</spage><epage>eabo4632</epage><pages>eabo4632-eabo4632</pages><issn>1946-6234</issn><eissn>1946-6242</eissn><eissn>1946-3242</eissn><abstract>Cancer vaccines have been shown clinically to drive tumor-reactive cell activation, proliferation, and effector function. Unfortunately, tumor eradication by treatment with cancer vaccines has been unsuccessful in many patients. Critical steps are under way to improve vaccine efficacy and combine them with immunotherapy and standard-of-care treatments.</abstract><cop>United States</cop><pub>The American Association for the Advancement of Science</pub><pmid>36350992</pmid><doi>10.1126/scitranslmed.abo4632</doi><orcidid>https://orcid.org/0000-0002-3439-9844</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1946-6234
ispartof Science translational medicine, 2022-11, Vol.14 (670), p.eabo4632-eabo4632
issn 1946-6234
1946-6242
1946-3242
language eng
recordid cdi_proquest_miscellaneous_2735166971
source Alma/SFX Local Collection
subjects Cancer
Cancer vaccines
Cancer Vaccines - therapeutic use
Cell activation
Humans
Immunotherapy
Neoplasms - therapy
Tumors
Vaccine efficacy
Vaccines
title What's next for cancer vaccines
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T17%3A53%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What's%20next%20for%20cancer%20vaccines&rft.jtitle=Science%20translational%20medicine&rft.au=Adamik,%20Juraj&rft.date=2022-11-09&rft.volume=14&rft.issue=670&rft.spage=eabo4632&rft.epage=eabo4632&rft.pages=eabo4632-eabo4632&rft.issn=1946-6234&rft.eissn=1946-6242&rft_id=info:doi/10.1126/scitranslmed.abo4632&rft_dat=%3Cproquest_cross%3E2735558152%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c381t-6b561d8d2d83c199f4f6137e683ad7d86750b2013daf617a0a6f60c9d2f01a2a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2735558152&rft_id=info:pmid/36350992&rfr_iscdi=true